Candidate vaccines protect macaques against primate immunodeficiency viruses.
The preclinical evaluation of the efficacy of potential vaccines against AIDS requires challenge models. The experimental infection of macaques with simian immunodeficiency virus, human immunodeficiency virus type 2 (HIV-2) or chimeric viruses have proven to be most valuable. The progress made using simian models to assess the efficacy and identify the correlates or mechanism of protection by whole inactivated virus, live attenuated virus or recombinant sub-unit vaccines is reviewed. It is possible to conclude from these studies that an effective AIDS vaccine is feasible. Furthermore, it is likely that these different vaccine approaches protect through distinct mechanisms. These results provide a scientific basis for the development and selection of suitable candidate human AIDS vaccines for testing in humans.
Stott
J
J
Division of Retrovirology, National Institute for Biological Standards and Control, Potters Bar, Herts, United Kingdom.
Hu
S L
SL
Almond
N
N
D016915:AIDS Vaccines / Q000276:immunology / Q000627:therapeutic use*; D000818:Animals; D004195:Disease Models, Animal; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D008251:Macaca; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D014613:Vaccines, Attenuated / Q000276:immunology / Q000627:therapeutic use; D015164:Vaccines, Inactivated / Q000276:immunology / Q000627:therapeutic use
D016915:AIDS Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated